Research Reports | Market Assessment
April 2014

Hyperphosphatemia | Decision Base | US | 2014

Payer and Physician Receptivity to Novel Treatments—Which Emerging Drugs Excite Them?

Hyperphosphatemia, or treatment of elevated serum phosphorous levels, typically found as a complication of chronic kidney disease (CKD), is a commercially compelling indication, a fact that is evident in an active pipeline. Today patients are treated with oral phosphate binders; one phosphate binder candidate was recently approved and another is in preregistration. Some of the phosphate binders in the pipeline may prove to also impact renal anemia parameters, which may result in less use of erythropoietin-stimulating agents (ESAs) and IV iron, in addition to the potential to reduce serum phosphorous. Some phosphate binders in development may also prove to have a compelling advantage in terms of pill burden, which is an extensive compliance problem in this difficult-to-treat patient population.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports